The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subcli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast Cancer Res Treat
Hauptverfasser: Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thürlimann, Beat, Ejlertsen, Bent, Bonnefoi, Hervé, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802157/
https://ncbi.nlm.nih.gov/pubmed/21892704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1741-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge